A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies)
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs TAK 003 (Primary) ; Yellow fever vaccine
- Indications Dengue
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.
- 21 Feb 2018 Planned End Date changed from 17 May 2019 to 4 May 2019.
- 21 Feb 2018 Planned primary completion date changed from 23 May 2018 to 25 May 2018.